Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01593748 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT01593748 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 90 participants.
The verdict
NCT01593748, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This study is for adult subjects with advanced tissue sarcoma. The study involves the drugs Pazopanib (Votrient), Gemcitabine (Gemzar), and Docetaxel (Taxotere). The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in participants with soft tissue sarcoma.
Interventions
- DRUG Gemcitabine and Pazopanib
- DRUG Gemcitabine and Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2012-09-27 |
| Est. Completion | 2019-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01593748
The ClinicalTrials.gov registry entry for NCT01593748 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine and Pazopanib is the first listed.
NCT01593748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01593748 about?
NCT01593748 is a clinical study titled "A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma". This study is for adult subjects with advanced tissue sarcoma. The study involves the drugs Pazopanib (Votrient), Gemcitabine (Gemzar), and Docetaxel (Taxotere). The purpose of this study is to test the effectiveness and safety of Gemcitabine and Pazopanib compared with Gemcitabine and Docetaxel in ...
What is the current status of trial NCT01593748?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2012-09-27. Estimated completion is 2019-04-24.
What interventions are being tested in trial NCT01593748?
The interventions under investigation include: Gemcitabine and Pazopanib (DRUG), Gemcitabine and Docetaxel (DRUG).
Who is sponsoring clinical trial NCT01593748?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.